You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 15, 2025

CLINICAL TRIALS PROFILE FOR ACETAMINOPHEN; IBUPROFEN


✉ Email this page to a colleague

« Back to Dashboard


505(b)(2) Clinical Trials for Acetaminophen; Ibuprofen

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
OTC NCT00245375 ↗ A Trial Comparing Combination Therapy of Acetaminophen Plus Ibuprofen Versus Tylenol #3 for the Treatment of Pain After Outpatient Surgery Completed McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. N/A 2005-01-01 Increasingly in general surgery, the investigators are conducting outpatient day surgery. Ambulatory surgery currently comprises 60 to 70% of surgeries performed in North America. These patients all require some form of analgesia which can be taken at home in the first few days after the surgery. The current standard at the investigators' centre and many others in the maritime provinces is to provide a prescription for oral acetaminophen plus codeine or oxycodone (Tylenol #3®, Percocet ®). Some patients may receive more potent opioids such as oral hydromorphone (Dilaudid®). Unfortunately, the most commonly prescribed medication (Tylenol #3®) is often poorly tolerated by patients, has several undesirable side effects, and may not provide effective pain relief. In the investigators' experience, non-steroidal anti-inflammatory drugs (NSAIDs) are uncommonly a routine addition to the home analgesic regimen. Tylenol #3®, in the investigators' experience and opinion, is a poor post surgical pain medication. They hope to show that a combination of ibuprofen and acetaminophen is better for pain relief after these procedures. The combination of acetaminophen and ibuprofen would be a safe, cheap, and readily available regimen. Unfortunately, as the prescribing practices of surgeons are old habits, it will require a very convincing argument to get them to change their practices. A randomized controlled trial comparing these two regimens, the investigators hope, would be a powerful enough argument. The hypothesis of this study, therefore, is that the pain control provided by a combination of acetaminophen plus ibuprofen (650 mg/400 mg four times per day) will be superior to Tylenol #3® (600 mg acetaminophen/60 mg codeine/15 mg caffeine four times per day). This study will attempt to enroll 150 patients in total. Eligible patients will be identified by their attending surgeon and contacted by study personnel. Patients who enroll in the study will undergo their surgery in the usual manner. After the surgery, in the recovery room, once they are ready to go home, they will be randomized to receive combination A or B and be given a week's worth of pain medication. They will then go home and take this medication as directed. They will record their pain intensity and pain relief once per day using a diary provided in the study package. One week after their surgery, they will return to the hospital clinic and be seen by the study nurse. They will hand over the diary and any unused medication. They will also be asked several questions regarding their overall satisfaction, incidence of side effects, and how long until they were pain free. The risks of participating in this study are minimal from the risks inherent to the procedures and medications the patients would receive within the standard of care. Ibuprofen is a commonly used NSAID which is widely available over the counter and has an established safety profile. The most common adverse effects of ibuprofen and other NSAIDs are gastrointestinal bleeding and ulceration. Other less common adverse effects include nephrotoxicity, hypersensitivity reactions, hepatic dysfunction (longterm use), and cognitive dysfunction. The investigators' patients will be selected to exclude those most at risk for these complications (see exclusion criteria). Acetaminophen has few side effects, with no adverse effects on platelet function and no evidence of gastric irritation.
OTC NCT00245375 ↗ A Trial Comparing Combination Therapy of Acetaminophen Plus Ibuprofen Versus Tylenol #3 for the Treatment of Pain After Outpatient Surgery Completed Nova Scotia Health Authority N/A 2005-01-01 Increasingly in general surgery, the investigators are conducting outpatient day surgery. Ambulatory surgery currently comprises 60 to 70% of surgeries performed in North America. These patients all require some form of analgesia which can be taken at home in the first few days after the surgery. The current standard at the investigators' centre and many others in the maritime provinces is to provide a prescription for oral acetaminophen plus codeine or oxycodone (Tylenol #3®, Percocet ®). Some patients may receive more potent opioids such as oral hydromorphone (Dilaudid®). Unfortunately, the most commonly prescribed medication (Tylenol #3®) is often poorly tolerated by patients, has several undesirable side effects, and may not provide effective pain relief. In the investigators' experience, non-steroidal anti-inflammatory drugs (NSAIDs) are uncommonly a routine addition to the home analgesic regimen. Tylenol #3®, in the investigators' experience and opinion, is a poor post surgical pain medication. They hope to show that a combination of ibuprofen and acetaminophen is better for pain relief after these procedures. The combination of acetaminophen and ibuprofen would be a safe, cheap, and readily available regimen. Unfortunately, as the prescribing practices of surgeons are old habits, it will require a very convincing argument to get them to change their practices. A randomized controlled trial comparing these two regimens, the investigators hope, would be a powerful enough argument. The hypothesis of this study, therefore, is that the pain control provided by a combination of acetaminophen plus ibuprofen (650 mg/400 mg four times per day) will be superior to Tylenol #3® (600 mg acetaminophen/60 mg codeine/15 mg caffeine four times per day). This study will attempt to enroll 150 patients in total. Eligible patients will be identified by their attending surgeon and contacted by study personnel. Patients who enroll in the study will undergo their surgery in the usual manner. After the surgery, in the recovery room, once they are ready to go home, they will be randomized to receive combination A or B and be given a week's worth of pain medication. They will then go home and take this medication as directed. They will record their pain intensity and pain relief once per day using a diary provided in the study package. One week after their surgery, they will return to the hospital clinic and be seen by the study nurse. They will hand over the diary and any unused medication. They will also be asked several questions regarding their overall satisfaction, incidence of side effects, and how long until they were pain free. The risks of participating in this study are minimal from the risks inherent to the procedures and medications the patients would receive within the standard of care. Ibuprofen is a commonly used NSAID which is widely available over the counter and has an established safety profile. The most common adverse effects of ibuprofen and other NSAIDs are gastrointestinal bleeding and ulceration. Other less common adverse effects include nephrotoxicity, hypersensitivity reactions, hepatic dysfunction (longterm use), and cognitive dysfunction. The investigators' patients will be selected to exclude those most at risk for these complications (see exclusion criteria). Acetaminophen has few side effects, with no adverse effects on platelet function and no evidence of gastric irritation.
OTC NCT00267293 ↗ Ibuprofen Alone and in Combination With Acetaminophen for Treatment of Fever Completed Children Youth and Family Consortium Phase 4 2006-01-01 Currently, when a child has fever either ibuprofen (e.g. Motrin, Advil) or acetaminophen (e.g. Tylenol) is given. Both Ibuprofen and Acetaminophen are approved for over the counter use for treatment of fever by the Food and Drug Administration (FDA). This study hopes to determine whether giving both medications together is better than giving one medication alone for the treatment of fever.
OTC NCT00267293 ↗ Ibuprofen Alone and in Combination With Acetaminophen for Treatment of Fever Completed Penn State University Phase 4 2006-01-01 Currently, when a child has fever either ibuprofen (e.g. Motrin, Advil) or acetaminophen (e.g. Tylenol) is given. Both Ibuprofen and Acetaminophen are approved for over the counter use for treatment of fever by the Food and Drug Administration (FDA). This study hopes to determine whether giving both medications together is better than giving one medication alone for the treatment of fever.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Acetaminophen; Ibuprofen

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00006299 ↗ Celebrex for Pain Relief After Oral Surgery Completed National Institute of Dental and Craniofacial Research (NIDCR) Phase 2 1999-12-01 This study will evaluate the effects of the new anti-inflammatory drug, Celebrex, on relieving pain after oral surgery. It is also designed to assess the drug's selective inhibition of a chemical called cyclooxygenase-2 and not its closely related form, cyclooxygenase-1. This selective inhibition allows pain alleviation without the adverse side effects (e.g., bleeding and stomach upset) often associated with anti-inflammatory drugs. Healthy volunteers who require removal of their third molars are eligible for this study. Participants will have oral surgery for tooth extraction after receiving a local anesthetic (lidocaine) in the mouth and a sedative (midazolam) through an arm vein. On the evening before and 1 hour before surgery, patients will be given a dose of either the standard anti-inflammatory drug ibuprofen (Advil, Nuprin, Motrin), or Celebrex, or a placebo (a pill with no active ingredient). After surgery, a small piece of tubing will be placed in each extraction site and tied to an adjacent tooth to hold it in place. Samples will be collected from the tubing to measure chemicals involved in pain and inflammation. Patients will stay in the clinic for up to 6 hours after surgery while the anesthetic wears off and will complete pain questionnaires. During that time, they may receive acetaminophen plus codeine (Tylenol 3), if needed, for pain. The tubing then will be removed and the patient discharged with standard pain medication.
NCT00110474 ↗ Glucosamine Unum In Die [Once A Day] Efficacy (GUIDE) Trial: Glucosamine Sulfate in Patients With Knee Osteoarthritis Completed Rottapharm Phase 3 2000-05-01 The primary objective of this study is to evaluate the efficacy and safety of glucosamine sulfate versus placebo on the symptoms of knee osteoarthritis after 6 months of treatment, using acetaminophen as a reference symptomatic medication.
NCT00129506 ↗ Comparing Methotrexate Followed by Misoprostol to Misoprostol Alone for Early Abortion Completed Ibis Reproductive Health Phase 4 2005-05-01 Background: In most countries in which abortion is legal, medical abortions are induced with mifepristone and misoprostol. Since mifepristone is expensive and unavailable in many countries, it is important to find other regimens. Methotrexate, which is used with misoprostol in Canada, is also difficult to obtain in many countries. Misoprostol is inexpensive and available in almost all countries. A report from Nigeria found that 98% of 100 women aborted within 24 hours of using misoprostol given both sublingually and vaginally. Method: This will be a randomized controlled trial of the usual regimen used in Canada, methotrexate 50 mg/m2 intramuscularly (IM) followed three days later by 800 mcg vaginal misoprostol to the Nigerian regimen of 400 mcg sublingual misoprostol with 400 mcg vaginal misoprostol. The main outcome measure will be a completed abortion within the first week with secondary outcome measures including total surgery rate, time to abortion, complications, pain, side effects and patient satisfaction. Rationale: If the investigators can find an inexpensive, easily available, method of medical abortion, it will save many lives in third world countries.
NCT00129506 ↗ Comparing Methotrexate Followed by Misoprostol to Misoprostol Alone for Early Abortion Completed Wiebe, Ellen, M.D. Phase 4 2005-05-01 Background: In most countries in which abortion is legal, medical abortions are induced with mifepristone and misoprostol. Since mifepristone is expensive and unavailable in many countries, it is important to find other regimens. Methotrexate, which is used with misoprostol in Canada, is also difficult to obtain in many countries. Misoprostol is inexpensive and available in almost all countries. A report from Nigeria found that 98% of 100 women aborted within 24 hours of using misoprostol given both sublingually and vaginally. Method: This will be a randomized controlled trial of the usual regimen used in Canada, methotrexate 50 mg/m2 intramuscularly (IM) followed three days later by 800 mcg vaginal misoprostol to the Nigerian regimen of 400 mcg sublingual misoprostol with 400 mcg vaginal misoprostol. The main outcome measure will be a completed abortion within the first week with secondary outcome measures including total surgery rate, time to abortion, complications, pain, side effects and patient satisfaction. Rationale: If the investigators can find an inexpensive, easily available, method of medical abortion, it will save many lives in third world countries.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Acetaminophen; Ibuprofen

Condition Name

Condition Name for Acetaminophen; Ibuprofen
Intervention Trials
Pain 30
Pain, Postoperative 22
Postoperative Pain 14
Fever 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Acetaminophen; Ibuprofen
Intervention Trials
Pain, Postoperative 57
Acute Pain 15
Fractures, Bone 14
Toothache 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Acetaminophen; Ibuprofen

Trials by Country

Trials by Country for Acetaminophen; Ibuprofen
Location Trials
United States 334
Canada 35
Brazil 4
New Zealand 3
Korea, Republic of 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Acetaminophen; Ibuprofen
Location Trials
California 31
New York 25
Pennsylvania 18
Texas 17
Utah 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Acetaminophen; Ibuprofen

Clinical Trial Phase

Clinical Trial Phase for Acetaminophen; Ibuprofen
Clinical Trial Phase Trials
Phase 4 99
Phase 3 40
Phase 2/Phase 3 7
[disabled in preview] 32
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Acetaminophen; Ibuprofen
Clinical Trial Phase Trials
Completed 121
Recruiting 45
Not yet recruiting 25
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Acetaminophen; Ibuprofen

Sponsor Name

Sponsor Name for Acetaminophen; Ibuprofen
Sponsor Trials
Lawson Health Research Institute 8
Johnson & Johnson Consumer and Personal Products Worldwide 8
Montefiore Medical Center 7
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Acetaminophen; Ibuprofen
Sponsor Trials
Other 277
Industry 66
U.S. Fed 14
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trials, Market Analysis, and Projections for Acetaminophen and Ibuprofen

Introduction

Acetaminophen and ibuprofen are two of the most widely used over-the-counter (OTC) medications for pain relief and fever reduction. The combination of these two drugs, often referred to as a fixed-dose combination (FDC), has been the subject of extensive clinical trials and market analysis. Here, we delve into the clinical trials, market trends, and future projections for this FDC.

Clinical Trials Overview

Safety and Tolerability

A pooled analysis of phase 1-3 clinical trials has shown that the FDC of ibuprofen and acetaminophen is well-tolerated and safe for OTC use. This analysis involved 1,477 participants across seven clinical trials, including pharmacokinetic, proof-of-concept, and multiple-dose trials. The results indicated that the FDC had an adverse event (AE) profile similar to its monocomponents, with nausea, vomiting, dizziness, headache, and feeling hot being the most common AEs reported. Notably, the incidence of AEs was lower in the active treatment groups compared to the placebo group[3].

Efficacy in Pain Relief

Clinical trials have also evaluated the efficacy of the FDC in relieving various types of pain. For instance, a study comparing ibuprofen plus acetaminophen to ibuprofen alone for acute low back pain found that adding acetaminophen did not significantly improve outcomes within one week. However, this study did not rule out the potential benefits of the FDC in other pain conditions[4].

Approval and Dosage

The FDA has approved Advil Dual Action with Acetaminophen, a product combining ibuprofen (125 mg) and acetaminophen (250 mg), for the temporary relief of minor aches and pains, including headaches, toothaches, backaches, menstrual cramps, and muscular aches. Clinical trials demonstrated that this FDC provided statistically significant pain relief compared to placebo and was effective over the proposed dosing interval[1].

Market Analysis

Global Market Size and Growth

The global ibuprofen API market, which includes the active pharmaceutical ingredient used in combination with acetaminophen, was valued at approximately USD 700.8 million in 2023. It is projected to grow at a compound annual growth rate (CAGR) of 1.17% from 2024 to 2030. This growth is driven by factors such as the increasing incidence of chronic diseases like rheumatoid arthritis and migraine, as well as the growing geriatric population[5].

Regional Market Trends

  • Asia Pacific: This region is expected to generate the highest share of the ibuprofen API market, driven by low manufacturing costs in countries like India and China. The healthcare expenditure in this region is also on the rise, further boosting market growth[2][5].
  • North America: The North American market is also anticipated to see significant growth, largely due to the rising prevalence of migraine and the widespread use of ibuprofen as an OTC medication. The sedentary lifestyle of the population in this region contributes to the higher incidence of migraine, thereby increasing the demand for ibuprofen and its combinations[2].

Application Segments

The arthritis segment is projected to dominate the ibuprofen API market, accounting for about 60% of the market share during the forecast period. This is due to the growing prevalence of arthritis globally, with millions of people suffering from this condition. Ibuprofen is particularly effective in treating rheumatoid arthritis and other inflammatory forms of arthritis[2].

Growth Drivers

Prevalence of Chronic Diseases

The increasing prevalence of chronic diseases such as rheumatoid arthritis, migraine, and influenza is a significant driver of the ibuprofen API market. For example, the World Health Organization estimates that there are approximately a billion instances of seasonal influenza annually, which necessitates the use of antipyretic and analgesic medications like ibuprofen and acetaminophen[2].

COVID-19 Impact

The COVID-19 pandemic has also influenced the demand for ibuprofen and acetaminophen. As COVID-19 often presents with fever and other symptoms that can be managed with these medications, their use has seen an uptick during the pandemic[2].

Healthcare Expenditure

Rising healthcare expenditure, particularly in the Asia Pacific region, is another factor driving the market. Increased spending on healthcare has led to higher demand for pharmaceuticals, including ibuprofen and its combinations[5].

Challenges

Regulatory Concerns

While the FDC of ibuprofen and acetaminophen has been approved, there are residual concerns regarding consumer safety and adherence to dosage limits. The FDA recommends daily limits for ibuprofen (1200 mg) and acetaminophen (2600 mg) to ensure safe use[1].

Competition from Other NSAIDs

The market also faces competition from other nonsteroidal anti-inflammatory drugs (NSAIDs) and analgesics. However, ibuprofen's tolerability and safety profile, particularly when compared to aspirin, make it a preferred choice for many consumers[2].

Key Takeaways

  • Clinical Safety and Efficacy: The FDC of ibuprofen and acetaminophen has been shown to be safe and effective in clinical trials.
  • Market Growth: The global ibuprofen API market is expected to grow at a CAGR of 1.17% from 2024 to 2030.
  • Regional Trends: Asia Pacific and North America are key regions driving market growth due to low manufacturing costs and rising healthcare expenditure.
  • Growth Drivers: Increasing prevalence of chronic diseases, COVID-19 impact, and rising healthcare expenditure are significant growth drivers.
  • Challenges: Regulatory concerns and competition from other NSAIDs are challenges the market faces.

FAQs

Q: What is the current market size of the ibuprofen API market?

The global ibuprofen API market was valued at approximately USD 700.8 million in 2023[5].

Q: What are the primary drivers of the ibuprofen API market growth?

The primary drivers include the increasing prevalence of chronic diseases, the impact of COVID-19, and rising healthcare expenditure[2][5].

Q: Which region is expected to dominate the ibuprofen API market?

The Asia Pacific region is expected to generate the highest share of the ibuprofen API market due to low manufacturing costs and rising healthcare expenditure[2][5].

Q: Is the FDC of ibuprofen and acetaminophen safe for OTC use?

Yes, clinical trials have shown that the FDC is well-tolerated and safe for OTC use, with an AE profile similar to its monocomponents[3].

Q: What are the recommended daily limits for ibuprofen and acetaminophen?

The FDA recommends daily limits of 1200 mg for ibuprofen and 2600 mg for acetaminophen to ensure safe use[1].

Sources

  1. FDA Approval Document: "Advil Dual Action with Acetaminophen® (Ibuprofen 125 mg plus Acetaminophen 250 mg) Tablets" - FDA[1].
  2. Research Nester Report: "Ibuprofen API Market Size & Share, Growth Trends 2037" - Research Nester[2].
  3. Pooled Safety Analysis: "Safety and tolerability of fixed-dose combinations of ibuprofen and acetaminophen: pooled analysis of phase 1-3 clinical trials" - PubMed[3].
  4. Clinical Trial Results: "Ibuprofen Plus Acetaminophen Versus Ibuprofen Alone for Acute Low Back Pain" - Wiley Online Library[4].
  5. Grand View Research Report: "Ibuprofen API Market Size, Share & Growth Report, 2030" - Grand View Research[5].

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.